Expert Interview
A look at the potential of psilocybin therapy and the Phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine.
Ticker(s): CMPSInstitution: University Hospitals
- treats 125 patients for depression total, 30% are treatment-resistant depression
- Areas of interest include Traduce dyskinesia, Treatment Resistant Depression (TRD), Cutting edge psychedelic research, Long acting antipsychotic injections, and Neuromodulation treatments for mood disorder
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
